Document:

Exhibit

Allegion plc
Incentive Stock Plan of 2013

Global Performance Stock Unit Award Agreement
For the 20XX - 20XX Performance Period
Dated as of [Grant Date] ("Grant Date")

Allegion plc (the “Company”) hereby grants to [insert name] (“Participant”) a performance stock unit award (the “PSUs”) pursuant to and subject to the terms and conditions set forth in the Company’s Incentive Stock Plan of 2013 (the “Plan”), including the terms and conditions for Performance-Based Awards as set forth in Section 8(b) of the Plan.  Unless otherwise defined herein, the terms defined in the Plan shall have the same meanings in this Performance Stock Unit Award Agreement (“the Award Agreement”).
Each PSU that vests pursuant to the terms of this Award Agreement shall provide Participant with the right to receive one ordinary share of the Company (the “Share”) on the issuance date described in Section 6 below.  The number of Shares subject to the PSUs, the performance and service vesting conditions applicable to such Shares, the date on which vested Shares shall become issuable and any further terms and conditions governing the PSUs shall be as set forth in this Award Agreement, including any country-specific terms set forth in the attached Appendix B for Participant’s country. 
		
	1.
	Number of Shares.  

The number of Shares subject to the PSUs at target performance level is [insert number of Shares subject to PSUs at target].  The maximum number of Shares subject to the PSUs is [insert maximum number of Shares subject to PSUs] Shares, provided, however, that the actual number of Shares that become issuable pursuant to the PSUs shall be determined in accordance with the fulfillment of certain performance conditions set forth in the attached Appendix A and the additional vesting requirements set forth in Section 5 below.
		
	2.
	Performance Period.

The performance period applicable to the PSUs is [insert performance period] (the “Performance Period”).
		
	3.
	Vesting.  

Participant’s right to receive Shares subject to the PSUs shall vest in accordance with the performance conditions set forth in the attached Appendix A and subject to the additional vesting requirements set forth in Section 5 below.
		
	4.
	Dividend Equivalents.

Participant shall be entitled to receive an amount equal to any cash dividend paid by the Company upon one Share for each PSU held by Participant when such dividend is paid (“Dividend Equivalent”), provided that (i) Participant shall have no right to receive the Dividend Equivalents unless and until the associated PSUs vest, (ii) Dividend Equivalents shall not accrue interest and (iii) Dividend Equivalents shall be paid in cash at the time that the associated PSUs vest.
		
	5.
	Termination of Employment.

(a)Group Termination; Job Elimination / Change / Relocation
If Participant’s employment terminates involuntarily by reason of (i) a group termination (including, but not limited to, terminations resulting from sale of a business or division, outsourcing of an entire function, reduction in workforce or closing of a facility) (a “Group Termination Event”) or (ii) job elimination, substantial change in the nature of Participant’s position or job relocation, a pro-rated number of Shares, based on the fulfillment of the performance vesting conditions as measured at the end of the Performance Period and 

determined by the Committee in Section 6 below and the number of days during the Performance Period that Participant was actively employed by the Company or an Affiliate, shall vest.  All other PSUs and associated Dividend Equivalents shall be forfeited and Participant shall have no right to or interest in such PSUs, the underlying Shares or any associated Dividend Equivalents.
(b)Termination Due to Death or Disability
If Participant’s employment terminates by reason of death or disability, a pro-rated number of Shares, based on the fulfillment of the performance vesting conditions at target level performance and the number of days during the Performance Period that Participant was actively employed by the Company or an Affiliate, shall vest.  All other PSUs and associated Dividend Equivalents shall be forfeited and Participant shall have no right to or interest in such PSUs, the underlying Shares or any associated Dividend Equivalents.
(c)Termination Due to Retirement
If Participant’s employment terminates after attainment of age 55 with at least 5 years of service (“Retirement”), and unless Participant’s employment terminates for cause, as defined in Section 5(d) below, a pro-rated number of Shares, based on the fulfillment of the performance vesting conditions as measured at the end of the Performance Period and determined by the Committee in Section 6 below and the number of days during the Performance Period that Participant was actively employed by the Company or an Affiliate, shall vest.  All other PSUs and associated Dividend Equivalents shall be forfeited and Participant shall have no right to or interest in such PSUs, the underlying Shares or any associated Dividend Equivalents. 
(d)Termination Due to Any Other Reason
If Participant’s employment terminates (i) for any reason or in any circumstances other than those specified in Sections 5 (a), (b) and (c) above or (ii) for cause in the circumstances specified in Section 5(c) above, all PSUs and any associated Dividend Equivalents shall be forfeited as of the date of termination of active employment and Participant shall have no right to or interest in such PSUs, the underlying Shares or any associated Dividend Equivalents.  For purposes of this Section 5(d), “cause” shall mean (x) any action by Participant involving willful malfeasance or willful gross misconduct having a demonstrable adverse effect on the Company or an Affiliate; (y) Participant being convicted of a felony under the laws of the United States or any state or district (or the equivalent in any foreign jurisdiction); or (z) any material violation of the Company’s code of conduct, as in effect from time to time.
		
	6.
	Settlement.

On a date as soon as practicable following the end of the Performance Period, the Committee shall certify the extent to which the performance vesting conditions set forth in Appendix A have been met (the “Certification Date”).  As soon as practicable thereafter, the Company shall cause to be issued to Participant Shares with respect to any PSUs that became vested on the Certification Date, provided that Participant was employed by the Company or an Affiliate on the Certification Date (unless otherwise provided in Sections 5(a),  (b) or (c) above).  Notwithstanding the foregoing, the Committee has the sole discretion to make downward adjustments to the award amount determined pursuant to Appendix A, including an adjustment such that no Shares are issued to Participant, regardless of the fulfillment of the performance vesting conditions set forth in Appendix A.  Notwithstanding the foregoing, if the Participant’s employment terminates in the circumstances set forth in Section 5(b) above, then on or as soon as practicable after such termination of employment, the Company shall cause to be issued to Participant Shares with respect to any PSUs that became vested pursuant to such section.  Shares issued pursuant to this Section 6 shall be fully paid and non-assessable.  Participant will not have any of the rights or privileges of a shareholder of the Company in respect of any Shares subject to the PSUs unless and until such Shares have been issued to Participant.
		
	7.
	Change in Control.

In the event of a Change in Control, the treatment of the PSUs will be governed by the terms of the Plan.
		
	8.
	Responsibility for Taxes.  

Participant acknowledges that, regardless of any action taken by the Company or, if different, Participant’s employer (the “Employer”), the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to Participant’s participation in the Plan and legally applicable to Participant (“Tax-Related Items”) is and remains Participant’s responsibility and may exceed the amount actually withheld by the Company or the Employer.  Participant further acknowledges that the Company and the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PSUs; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the PSUs to reduce or eliminate Participant’s liability for Tax-Related Items or achieve any particular tax result.  Further, if Participant is subject to Tax-Related Items in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
To satisfy any withholding obligations of the Company and/or the Employer with respect to Tax-Related Items, the Company will withhold Shares otherwise issuable upon settlement of the PSUs.  Alternatively, or in addition, in connection with any applicable taxable or tax withholding event, Participant authorizes the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: 
		
	(a)
	withholding from Participant’s wages or other cash compensation paid to Participant by the Company or the Employer, 

		
	(b)
	withholding from proceeds of the sale of Shares acquired upon settlement of the PSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on Participant’s behalf pursuant to this authorization without further consent) and/or 

		
	(c)
	requiring Participant to tender a cash payment to the Company or an Affiliate in the amount of the Tax-Related Items; 

provided, however, that if Participant is a Section 16 officer of the Company under the Act, the withholding methods described in this Section 8(a), (b) and (c) will only be used if the Committee (as constituted to satisfy Rule 16b-3 of the Act) determines, in advance of the applicable withholding event, that one such withholding method will be used in lieu of withholding Shares. 
The Company may withhold for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates, in which case Participant will receive a refund of any over-withheld amount in cash and will have no entitlement to the equivalent amount in Shares.  The Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares, if Participant fails to comply with his or her obligations in connection with the Tax-Related Items.
		
	9.
	Nature of Grant.  

In accepting the PSUs, Participant acknowledges, understands and agrees that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and it may be amended, altered or discontinued by the Company at any time, to the extent permitted by the Plan;
(b)the grant of the PSUs is voluntary and occasional and does not create any contractual or other right to receive future grants of performance stock units, or benefits in lieu of performance stock units, even if performance stock units have been granted in the past; 
(c)all decisions with respect to future performance stock unit grants, if any, will be at the sole discretion of the Company; 
(d)Participant is voluntarily participating in the Plan; 
(e)the PSUs and the Shares subject to the PSUs, and the income and value of same, are not intended to replace any pension rights or compensation; 
(f)the PSUs and the Shares subject to the PSUs, and the income and value of same, are not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; 
(g)unless otherwise agreed with the Company, the PSUs and the Shares subject to the PSUs, and the income and value of same, are not granted as consideration for, or in connection with, services Participant may provide as a director of an Affiliate;
(h)the PSU grant and Participant’s participation in the Plan will not create a right to employment or be interpreted as forming an employment or service contract with the Company, the Employer or any Affiliate and will not interfere with the ability of the Company, the Employer or any Affiliate, as applicable, to terminate Participant's employment or service relationship (if any);
(i)the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty; 
(j)no claim or entitlement to compensation or damages shall arise from forfeiture of the PSUs resulting from Participant ceasing to provide employment or other services to the Company or the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant's employment agreement, if any) or from cancellation of the PSUs or recoupment of any financial gain resulting from the PSUs as described in Section 16 below;
(k)for purposes of the PSUs, Participant’s employment or other service relationship will be considered terminated as of the date Participant is no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant's employment agreement, if any), and, unless otherwise expressly provided in this Award Agreement or determined by the Company, Participant’s right to vest in the PSUs under the Plan, if any, will terminate as of such date, or will be measured with reference to such date in the case of a Group Termination Event (or other termination described in Section 5(a) above), Retirement or termination due to death or disability, and will not be extended by any notice period (e.g., Participant’s period of active service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where Participant is employed or the terms of Participant's employment agreement, if any); the Committee shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of the PSUs (including whether Participant may still be considered to be providing services while on a leave of absence);
(l)unless otherwise provided in the Plan or by the Company, in its discretion, the PSUs and the benefits evidenced by this Award Agreement do not create any entitlement to have the PSUs or any such benefits transferred to, or assumed by another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and    

(m)neither the Company, nor the Employer nor any Affiliate will be liable for any foreign exchange rate fluctuation between Participant’s local currency and the United States Dollar that may affect the value of the PSUs or of any amounts due to Participant pursuant to the settlement of the PSUs or the subsequent sale of any Shares acquired upon settlement.
		
	10.
	No Advice Regarding Grant. 

The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant’s participation in the Plan or his or her acquisition or sale of the underlying Shares.  Participant should consult with his or her own personal tax, legal and financial advisors regarding Participant’s participation in the Plan before taking any action related to the Plan.
		
	11.
	Data Privacy.  

Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant’s personal data as described in the Award Agreement and any other PSU grant materials by and among, as applicable, the Employer, the Company and any Affiliate for the purpose of implementing, administering and managing Participant’s participation in the Plan and any other purposes permitted by the Employer’s applicable privacy notice.
Participant understands that the Company and the Employer may hold certain personal information about Participant, including, but not limited to, Participant’s name, home address, email address and telephone number, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all PSUs or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Participant’s favor(“Data”) for the purpose of implementing, administering and managing the Plan and any other purposes permitted by the Employer’s applicable privacy notice.
Participant understands that Data may be transferred to UBS, or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan.  Participant understands that the recipients of Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than Participant’s country.  Participant understands that he or she may request a list with the names and addresses of any potential recipients of Data by contacting his or her local human resources representative.  Participant authorizes the Company, UBS and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of implementing, administering and managing Participant’s participation in the Plan and any other purposes permitted by the Employer’s applicable privacy notice.  Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant’s participation in the Plan.  Participant understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing Participant’s local human resources representative.  Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis.  If Participant does not consent, or if Participant later seeks to revoke his or her consent, Participant's employment status or service with the Employer will not be affected; the only consequence of refusing or withdrawing consent is that the Company would not be able to grant PSUs or other equity awards to Participant or administer or maintain such awards.  Therefore, Participant understands that refusing or withdrawing his or her consent may affect his or her ability to participate in the Plan.  For more information on the consequences of Participant’s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.

Finally, upon request of the Company or the Employer, Participant agrees to provide any additional executed data privacy consent forms (or any other agreements or consents) that the Company and/or the Employer may deem necessary to obtain from Participant for the purpose of administering his or her participation in the Plan in compliance with the data privacy laws in Participant’s country, either now or in the future. Participant understands and agrees that he or she will not be able to participate in the Plan if Participant fails to provide any such consent or agreement requested by the Company and/or the Employer.
Participant further understands and acknowledges that the processing activity, including communication, the transfer of Data abroad, including outside of the European Economic Area, as herein specified and pursuant to applicable laws and regulations, may not require Participant’s consent thereto as the processing is necessary to performance of contractual obligations related to implementation, administration and management of the Plan, which represents the legal basis for the processing and, in such cases, Participant understands and acknowledges that Company and Employer reserve the right to use such legal basis for processing.
		
	12.
	Electronic Delivery and Participation.  

The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan by electronic means or to request Participant’s consent to participate in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.
		
	13.
	Insider Trading/Market Abuse Laws.

Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions including, but not limited to, the United States and Participant’s country of residence, which may affect Participant’s ability to accept, acquire, sell or otherwise dispose of Shares or rights to Shares (e.g., PSUs) or rights linked to the value of Shares under the Plan during such times as Participant is considered to have “inside information” regarding the Company (as defined by the laws in Participant’s country).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Company’s insider trading policy.
		
	14.
	Country-Specific Terms and Conditions.

Notwithstanding any provisions in this Award Agreement, the PSUs and the Shares subject to the PSUs shall be subject to any special terms and conditions for Participant’s country set forth in the attached Appendix B. Moreover, if Participant relocates to one of the countries included in Appendix B, the special terms and conditions for such country will apply to Participant to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  Appendix B constitutes part of this Award Agreement.
		
	15.
	Imposition of Other Requirements.

This grant is subject to, and limited by, all applicable laws and regulations and to such approvals by any governmental agencies or national securities exchanges as may be required.  Participant agrees that the Company shall have unilateral authority to amend the Plan and this Award Agreement without Participant’s consent to the extent necessary to comply with securities or other laws applicable to the issuance of Shares.  The Company reserves the right to impose other requirements on Participant’s participation in the Plan, on the PSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.

		
	16.
	Recoupment Provision.

In the event that Participant commits fraud or engages in intentional misconduct that results in a need for the Company to restate its financial statements, then the Committee may direct the Company to (i) cancel any outstanding portion of the PSUs and (ii) recover all or a portion of the financial gain realized by Participant through the PSUs.  Further, Participant agrees that the PSUs and any financial gain realized by Participant through the PSUs shall be subject to forfeiture and/or repayment to the Company to the extent required to comply with any applicable laws or the rules and regulations of the securities exchange or inter-dealer quotation system on which the Shares are listed or quoted, including, without limitation, pursuant to Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. 
		
	17.
	Choice of Law and Venue.  

The PSU grant and the provisions of this Award Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to such state’s conflict of laws or provisions, as provided in the Plan.  For purposes of litigating any dispute that arises under this grant or this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of Delaware and agree that such litigation shall be conducted in the courts of New Castle County, Delaware, or the federal courts for the United States for the District of Delaware, where this grant is made and/or to be performed. 
		
	18.
	Severability.  

The provisions of this Award Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
		
	19.
	Language.  

If Participant has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.
		
	20.
	Waiver.  

Participant acknowledges that a waiver by the Company of breach of any provision of this Award Agreement shall not operate or be construed as a waiver of any other provision of this Award Agreement, or of any subsequent breach by Participant or any other participant in the Plan.
		
	21.
	Acknowledgement of Availability of Plan Prospectus.

Participant acknowledges that he or she has been provided with access to a copy of the Plan prospectus and Plan document, links to both of which are available below:
[EMBED LINK TO PLAN PROSPECTUS]  [EMBED LINK TO PLAN DOCUMENT]
Paper copies of the Plan prospectus and Plan document are also available upon request from the Company’s stock administration department, at the contact information provided on the cover page of the Plan prospectus.
		
	22.
	Acknowledgement & Acceptance within 120 Days.  

This grant is subject to acceptance, within 120 days of the Grant Date, by electronic acceptance through the website of UBS, the Company’s stock plan administrator.  Failure to accept the PSUs within 120 days of the Grant Date may result in cancellation of the PSUs.

Signed for and on behalf of the Company:

__________________________________                    
David D. Petratis
Chairman and Chief Executive Officer
Allegion plc

This document constitutes part of a prospectus covering securities that have been registered under the Securities Act of 1933aimt-ex101_312.htm

Exhibit 10.1

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

AMENDED AND RESTATED
SUPPLY AGREEMENT

This Amended and Restated Supply Agreement (the “Agreement”) is entered into as of January 10, 2018 (the “Effective Date”) by and between Aimmune Therapeutics, Inc., a Delaware corporation, having its principal place of business at 8000 Marina Boulevard, Suite 300, Brisbane, California 94005 (“Aimmune”) and Golden Peanut Company, LLC, a Georgia limited liability company, having its principal place of business at 100 North Point Center East, Suite 400, Alpharetta, Georgia 30022 (together with its Affiliates and subsidiaries, collectively “Supplier”). Aimmune and Supplier are referred to collectively as the “Parties” and individually as a “Party”.

RECITALS

WHEREAS Aimmune, which was previously known as the Allergen Research Corporation, is engaged in the research and development of immunotherapy treatments directed at peanut allergies;

WHEREAS Supplier is in the business of supplying food-grade peanut flour;

WHEREAS Aimmune desires to engage Supplier to supply quantities of Product, as defined below, to be incorporated into Aimmune’s oral immunotherapy treatment for peanut allergies, and Supplier desires to provide such supply, pursuant to the terms and conditions set forth in this Agreement;

WHEREAS Aimmune and Supplier have previously entered into that certain Supply Agreement dated as of October 13, 2014 (the “Prior Agreement”);

WHEREAS Aimmune and Supplier desire to amend, restate and otherwise supersede in its entirety the Prior Agreement with this Agreement; and

WHEREAS Aimmune and Supplier have entered into a Securities Issuance Agreement of even date herewith (the “Securities Agreement”) pursuant to which Aimmune will issue in a private placement 300,000 shares of Aimmune’s common stock, par value $0.0001 per share, to Supplier as an inducement for Supplier to enter into this Agreement.

NOW THEREFORE, in consideration of the above premises and the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto mutually agree as follows:

AGREEMENT

Article I
DEFINITIONS

When used in this Agreement, each of the following terms shall have the respective meanings provided below:

 

 

Section 1.1“Affiliate” means any corporation, firm, partnership, or other entity that controls, is controlled by, or is under common control with a Party. For purposes of this definition, “control” shall mean the ownership of at least fifty percent (50%) of the voting share capital of such entity or any other comparable equity or ownership interest.

Section 1.2“Agreement Term” shall have the meaning set forth in Section 5.1.

Section 1.3“Applicable Law” means all laws, ordinances, rules, and regulations within the countries of the Territory applicable to the processing and supply of Product.

Section 1.4“Confidential Information” has the meaning set forth in Section 7.1 below. 

Section 1.5“Contract Year” means each individual year within the Supply Term. 

Section 1.6“FDA” means the U.S. Food and Drug Administration, or any successor thereto.

Section 1.7“Field” means oral immunotherapy for the treatment or cure of peanut allergy, whether as a single agent or in combination with one or more additional agents.

Section 1.8“First Delivery Date” has the meaning set forth in Section 2.1 below.

Section 1.9“Force Majeure Event” has the meaning set forth in Section 8.5 below.

Section 1.10“Forfeiture Expiration Date” means the first date that no Shares (as defined in the Securities Agreement) are subject to forfeiture pursuant to Section 3.2 of the Securities Agreement.

Section 1.11“Initial Supply Term” means the time period commencing upon the First Delivery Date and continuing in effect for a period of ten (10) years.

Section 1.12“Minimum Annual Volume Commitment” or “MAV Commitment” has the meaning set forth in Section 2.4 below.

Section 1.13“Product” means (a) prior to the Reversion Date, the food-grade peanut flour products listed on Exhibit C-1 or (b) after the Reversion Date, the food-grade peanut flour product listed on Exhibit C-2.

Section 1.14“Purchase Order” has the meaning set forth in Section 2.2 below. 

Section 1.15“Renewal Term” has the meaning set forth in Section 5.1 below.

Section 1.16“Reversion Date” shall mean the first date (if any) following the Effective Date and prior to the Forfeiture Expiration Date on which the price per share of Aimmune’s common stock on the Nasdaq Global Select Market is less than [***] (as adjusted for stock splits, combinations, stock dividends and the like, which such events also impact the Shares (as defined in the Securities Agreement) and occurring after the Effective Date), using the [***]day average 

2

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

closing price (“ACP”); provided, however, that a Reversion Date shall not be deemed to have occurred if at any time prior to such date the number of Shares Released (as defined in the Securities Agreement) to GPC pursuant to the Securities Agreement (whether or not then‐currently held by GPC or any Affiliate of GPC), multiplied by the price per share of Aimmune’s common stock on the Nasdaq Global Select Market, using the [***]day ACP, is greater than or equal to [***].

Section 1.17“Specifications” means the specifications for Product, attached hereto as Exhibit B, as may be amended from time to time by mutual agreement of the Parties.

Section 1.18“Supply Term” means the time period commencing upon the first day of the Initial Supply Term and either ending upon the expiration of the Initial Supply Term or, if Aimmune exercises its option to renew the Agreement pursuant to Section 5.1 herein, ending upon the expiration of the Renewal Term.

Section 1.19“Territory” means (a) prior to the Reversion Date, worldwide (i.e., all countries, along with any and all possessions and territories of each country) or (b) after the Reversion Date, the United States of America, Canada, Mexico, the European Union (which shall include the member states of the European Union as of the Effective Date) and Japan along with any and all possessions and territories of the foregoing countries.

Section 1.20“Treatment” means Aimmune’s oral immunotherapy treatment for peanut allergies.

Article II
FORECASTS AND PURCHASING

Section 2.1On or about ninety (90) days prior to Aimmune’s requested date for its first delivery of Product for commercial use (the “First Delivery Date”), Aimmune shall provide Supplier with a forecast of its monthly anticipated quantities of Product for the twelve (12) month period commencing upon the First Delivery Date. The parties agree that the First Delivery Date is intended to occur approximately one year prior to the date that Aimmune, in its good faith judgment, expects to receive approval of the Treatment from the FDA or the EMA. Thereafter, by the end of each calendar quarter, Aimmune shall update this forecast to cover the twelve (12) month period beginning with the next calendar quarter. For each forecast, the Product quantities set forth for the first quarter (three (3) calendar months) of the forecast period shall be binding and the Product quantities set forth for the remaining nine months of the forecast period shall be non-binding but shall represent Aimmune’s best estimate of such Product quantities, using commercially reasonable efforts. For the first forecast only, the time from the First Delivery Date to the end of the then-current calendar quarter shall be added to and considered part of the first full calendar quarter of the first forecast and shall be binding. For clarity, if Aimmune reasonably expects to receive FDA or EMA approval of the Treatment on [***], (i) the First Delivery Date shall be [***], (ii) Aimmune shall provide the first forecast to Supplier on or about [***], (iii) the first quarter of the first forecast shall begin on [***] and end on [***], (iv) the second quarter of the first forecast shall begin on [***], and (v) the first twelve (12) month forecast period shall end on [***]. For the avoidance of doubt, prior to the First Delivery Date, Aimmune may order small quantities of Product from Supplier for non-commercial use (including but not limited to 

3

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

conducting clinical trials), and in no event shall the date of any such order or the delivery date of any such order be considered the First Delivery Date.

Section 2.2Together with the submission of each forecast, Aimmune shall submit a purchase order specifying the requested delivery dates for the quantities of Product Aimmune is committing to order in the first quarter of such forecast (each, a “Purchase Order”). Supplier shall accept all Purchase Orders for a given calendar quarter that are submitted in compliance with this Agreement. At Aimmune’s discretion, Aimmune may purchase additional quantities of Product in excess of the quantities in the forecast for such quarter.

Section 2.3Aimmune agrees to purchase from Supplier its total requirements for Product during the Agreement Term, provided that Supplier continues to (i) supply Aimmune with Product conforming to the Specifications, (ii) deliver Product conforming to the Specifications to Aimmune in such quantities and at such times as required by Aimmune and (iii) comply with its obligations under Article 3. In the event that Supplier does not, or is unable to, meet its obligations as set forth in (i), (ii) and (iii) above, Aimmune shall be free to purchase Product from third parties, in amounts sufficient to meet Aimmune’s requirements, until such time as Supplier resumes supply of Product to Aimmune meeting such obligations.

Section 2.4Aimmune hereby agrees to either (a) purchase the minimum annual volumes of Product conforming to the Specifications during the Supply Term (“Minimum Annual Volume Commitment” or “MAV Commitment”) listed in the table below or (b) pay to Supplier within the thirty (30) day period following the applicable Contract Year an amount equal to the difference between the volume of Product that would have been purchased if Aimmune met the MAV Commitment in such Contract Year and the volume of Product actually purchased by Aimmune in such Contract Year, [***]

		
	
Contract Year
	
Minimum Annual Volume

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

 

Article III
SUPPLY AND DELIVERY

Section 3.1During the Agreement Term, Supplier shall supply to Aimmune Product conforming to the Specifications, and produced in accordance with Applicable Law and with the terms and conditions of this Agreement, at the prices set forth in Article IV herein. Aimmune’s Affiliates may purchase Product directly from Supplier in accordance with the terms and conditions of this Agreement.

4

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

Section 3.2Supplier shall maintain sufficient inventories of Product conforming to the Specifications to meet Aimmune’s forecasted requirements therefor.

Section 3.3Subject to Aimmune’s satisfying the conditions set forth in Section 2.3 and Section 2.4 above, Supplier hereby agrees that it shall cease any and all sales of Product to third parties in the Territory who Supplier knows or has reason to know will use the Product within the Field, and shall not sell Product to any such third party in the Territory during the Agreement Term. In the event that Supplier becomes aware, whether by good faith, substantiated notification from Aimmune or otherwise, that a third party to which Supplier has been supplying Product intends to use such Product within the Field, Supplier shall immediately cease all sales of Product to such third party and shall not resume such sales for the remainder of the Agreement Term or until Supplier has a good faith, substantiated reason to believe that the customer no longer intends to use Product in the Field, whichever is sooner.

Section 3.4Supplier shall ship the Product FOB (lncoterms 2010) [***]. Title in the Product shall pass to Aimmune when the Product is loaded on the first transportation carrier.

Section 3.5In the event that Supplier either (a) delivers Product that fails to conform to the Specifications, or (b) fails to ship Product to Aimmune within thirty (30) days of the applicable delivery date specified on a Purchase Order accepted by Supplier, Aimmune shall have the right, in its sole discretion, to require either (x) a refund of the purchase price paid for the nonconforming or undelivered Product, as applicable, or (y) the prompt replacement or delivery of such non-conforming or undelivered Product.

Section 3.6Supplier will provide Aimmune with notice of any material change to the methods or materials that Supplier uses to produce the Product. Such notice will describe the material change in reasonable detail. Where reasonably practicable, Supplier will provide Aimmune with such notice at least sixty (60) days prior to the material change of method or material.

Section 3.7Within sixty (60) days after the Effective Date and on each anniversary of the Effective Date, Supplier agrees to advise in writing all wholesalers and distributors to whom it sells Product that Supplier’s Product cannot be sold or distributed to any customer in the Field in the Territory. In the event that Supplier becomes aware, whether by notification from Aimmune or otherwise, that a distributor or wholesaler of Supplier’s Product has distributed or sold Supplier’s Product to a customer that used or intends to use such Product within the Field, Supplier shall immediately notify such distributor or wholesaler and instruct such distributor or wholesaler to cease all distribution or sales of Supplier’s Product to such customer. For the avoidance of doubt, nothing herein shall restrict a wholesaler or distributor to whom Supplier sells Products from selling peanut flour (so long as such peanut flour is not a Product) supplied by someone other than Supplier.

Section 3.8Supplier agrees not to knowingly provide any information or data to any third party (or to any regulatory authority at the request of a third party) that would in any way support the development or commercialization by such third party or any of such third party’s licensees, partners or agents of a product in the Field. For example, Supplier will not knowingly 

5

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

provide information or data to a third party that would allow such third party to begin clinical trials of or seek regulatory approval to market or sell a product in the Field.

Section 3.9In the event that the Supplier receives on or before the [***] anniversary of the Effective Date, and is inclined to pursue, a bona fide proposal or offer by a third party (a “Third-Party Offer”) to purchase an existing peanut flour product that is not a Product, or to develop and/or purchase a new peanut flour product, in each case where Supplier knows or has reason to know that such new or existing product will be used within the Field, the Supplier, within ten (10) days following receipt of such Third-Party Offer, shall provide Aimmune with written notice of such Third-Party Offer, including the material terms and conditions thereof, subject to any confidentiality obligations that Supplier may have to the third party (the “Third‐Party Offer Notice”), and Aimmune shall have ten (10) days following receipt of such Third-Party Offer Notice (the “Aimmune Offer Period”) to submit to the Supplier a written offer to purchase or develop such existing or new peanut flour product on terms and conditions at least as favorable to the Supplier as those proposed by the Third Party Offer (an “Aimmune Qualifying Offer”). During the Aimmune Offer Period, Supplier cannot negotiate, discuss or enter into any agreement in respect of, the Third-Party Offer. In the event that Aimmune fails to submit an Aimmune Qualifying Offer within the Aimmune Offer Period, the Supplier may consummate the transaction contemplated by the Third-Party Offer; provided, however, that the transaction contemplated by such Third-Party Offer is consummated within the Closing Period (as defined below). In the event that the transaction contemplated by such Third-Party Offer is not consummated within the Closing Period (as defined below), the right of first refusal provided by this Section 3.9 shall revive, and Aimmune again shall have the right to submit an Aimmune Qualifying Offer pursuant to this Section 3.9. The “Closing Period” shall mean the period commencing on the date on which Aimmune fails to submit an Aimmune Qualifying Offer pursuant to this Section 3.9 and ending one hundred and twenty (120) days thereafter. For the avoidance of doubt, the terms and conditions of this Section apply to each Third-Party Offer received by the Supplier. In the event that Aimmune submits an Aimmune Qualifying Offer pursuant to this Section 3.9, Aimmune shall proceed to consummate the transaction contemplated by the Aimmune Qualifying Offer promptly and within a period of time commensurate with that contemplated by the Third-Party Offer.

Article IV
PRICING AND PAYMENT TERMS

Section 4.1The price for Product conforming to the Specifications shall be equal to [***], attached hereto as Exhibit A. The Product price does not include any applicable excise, sales, use, withholding, luxury, turnover (value added), purchase, or similar tax of any kind. Aimmune shall be liable for payment of all such taxes, fees, and charges.

Section 4.2Aimmune hereby acknowledges that Supplier may, from time to time , make changes to its [***] for Product; provided, however, that (i) any such price changes shall not go into effect until January 1 of the following year and shall apply only to Purchase Orders submitted after that date, and (ii) in no event shall Supplier make any changes to the price of Product after November 1 of any year during the Supply Term. The foregoing shall not apply to Section 4.4 herein.

6

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

Section 4.3Supplier shall invoice Aimmune for amounts due promptly after each delivery. All invoices shall be due and payable thirty (30) days from the date of the applicable invoice; provided, however, that Supplier may change the foregoing time period upon advance written notice to Aimmune in the event that Aimmune’s credit or financial responsibility has become, in Supplier’s discretion, unsatisfactory. In the event any payments become past due, such overdue amounts shall be subject to interest accrued at an annual rate equal to the maximum interest rate permitted by law.

Section 4.4In the event that Aimmune fails to satisfy its obligations under Sections 2.3 or 2.4, Supplier shall (i) be relieved of the obligations set forth in Section 3.3 herein, and (ii) have the option to renegotiate the Product pricing applicable to Aimmune.

Article V
TERM AND TERMINATION

Section 5.1The term of the Agreement will commence as of the Effective Date and, unless earlier terminated pursuant to this Article 5, shall continue until the expiration of the Initial Supply Term (“Agreement Term”). Upon expiration of the Initial Supply Term, Aimmune shall have the option to renew the Agreement for an additional term of five (5) years by written notice to Supplier provided no less than 6 months prior to the expiration of the Initial Supply Term (the “Renewal Term”), in which case the Agreement Term shall continue until expiration of the Renewal Term, unless earlier terminated pursuant to this Article 5.

Section 5.2Aimmune may terminate the Agreement at will at any time, for any reason, upon sixty (60) days’ advance written notice to Supplier. For the avoidance of doubt, if Aimmune terminates the Agreement for any reason other than those set forth in Section 5.4 hereunder, there shall be no forfeiture of Supplier’s shares under the Securities Agreement.

Section 5.3[Section Reserved]

Section 5.4This Agreement may be terminated in its entirety by either Party immediately upon written notice upon the occurrence of any of the following events:

(a)A Party’s material breach of any representation, warranty, covenant, or obligation contained in this Agreement that is not excused by a Force Majeure Event and is not cured within thirty (30) days’ of receiving written notice from the non-breaching Party setting forth the details of such breach;

(b)Due to a Force Majeure Event, a Party fails to fulfill any of its obligations under this Agreement for a continuous period of 120 days or more; or

(c)The other Party (i) becomes insolvent, (ii) makes an assignment for the benefit of creditors, (iii) files a voluntary petition in bankruptcy, (iv) an involuntary petition in bankruptcy filed against it and is not dismissed within ninety (90) days of filing, or (v) has a receiver appointed for a substantial portion of its assets.

Section 5.5Upon termination or expiration of this Agreement, Supplier shall (i) fulfill any Purchase Orders accepted prior to such termination or expiration, if such termination is not 

7

 

 

due to Aimmune’s material breach (ii) cease any ongoing production of Product intended for fulfillment of any subsequent purchase orders expected pursuant to forecasts received prior to such termination or expiration, and (iii) limit further expenses associated with such ongoing production. Following any termination or expiration of this Agreement, Aimmune shall be liab le for the following (as invoiced by Supplier): (i) all orders produced or in production on behalf of Aimmune pursuant to a Purchase Order, and (ii) all expenses incurred or committed by Supplier on Aimmune’s behalf.

Section 5.6Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued to the benefit of either Party prior to such expiration or termination, including without limitation Aimmune’s payment obligations to Supplier. Termination of this Agreement for any reason shall not affect any obligations which, from the context hereof, are intended to survive termination of this Agreement.

Article VI
REPRESENTATIONS, WARRANTIES, AND COVENANTS

Section 6.1Supplier represents, warrants, and covenants as follows:

(a)All Product delivered hereunder shall, at the time of shipment, be free and clear of any liens or encumbrances, and shall conform to the Specifications;

(b)All Product delivered hereunder shall be produced in compliance with all Applicable Laws, including without limitation the Fair Labor Standards Act of 1938, as amended; and

(c)To Supplier’s knowledge, the manufacture, use and sale of the Product does not and will not infringe upon any third party’s intellectual property.

Section 6.2Aimmune represents, warrants and covenants that the Product will be used by it in a manner that complies with the laws, rules, and regulations of any governmental regulatory authority involved in regulating any aspect of the development, manufacture, market approval, sale, distribution, packaging, or use of drug products, including, but not limited to, the FDA, the Canadian Health Products and Food Branch, and The European Medicines Agency(“EMA”).

Section 6.3Each Party represents, warrants, and covenants that, as of the Effective Date, it:

(a)is a corporation duly organized and validly existing and in good standing under the laws of its jurisdiction of the organization;

(b)is qualified or licensed to do business and in good standing in every jurisdiction where such qualification or licensing is required;

(c)has the corporate power and authority to negotiate, execute, deliver, and perform its obligations under this Agreement;

8

 

 

 

(d)has no obligations or commitments to third parties inconsistent or in conflict with this Agreement and, during the Agreement Term, will not enter into any obligations or commitments to third parties inconsistent with or in conflict with this Agreement; and

(e)has secured all consents and authorizations necessary to enter into this Agreement and proceed with the undertakings required herein and the execution, delivery and performance of this Agreement have been duly and validly authorized.

Section 6.4For the avoidance of doubt, it is Aimmune’s sole responsibility to determine the suitability of the Product for use in the Field and Supplier shall have no responsibilities in relation thereto hereunder.

Section 6.5EXCEPT AS EXPRESSLY PROVIDED HEREIN, SUPPLIER EXPRESSLY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED, OR STATUTORY, AS TO ANY GOODS DELIVERED IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

Article VII
CONFIDENTIALITY

Section 7.1Subject to the provisions of this Article VII, the terms of this Agreement and any confidential or proprietary information or trade secrets disclosed by either Party to the other prior to or during the Agreement Term (collectively, the “Confidential Information”) shall be treated as confidential.

Section 7.2Except as expressly permitted under this Agreement, each Party agrees that, during the Agreement Term and any Renewal Term, and for a period of five (5) years thereafter, it shall:

(a)Use the Confidential Information only for the purpose of satisfying its obligations under this Agreement; and

(b)Not disclose the Confidential Information to any third party.

Section 7.3The restrictions in this Article VII shall not apply to any Confidential Information the receiving Party can demonstrate:

(a)is or has become publicly available through no fault of the receiving Party or its employees;

(b)is received from a third party lawfully in possession of such information and lawfully empowered to disclose such information;

(c)was rightfully in the possession of the receiving Party prior to its disclosure by the disclosing Party, as evidenced by written records of the receiving Party; or

9

 

 

 

(d)is independently developed by employees or consultants of the receiving Party without use of Confidential Information of the disclosing Party, as evidenced by written records of the receiving Party.

Section 7.4Notwithstanding the foregoing, each Party may disclose the other Party’s Confidential Information to any of its Affiliates, officers, directors, employees, agents, and representatives, that (i) need to know such Confidential Information for the purpose of performing under this Agreement, (b) are advised of the contents of this Article, and (c) are bound by confidentiality and non-use obligations equivalent to those in this Article VII. Additionally, each Party may disclose the other Party’s Confidential Information to the extent the other Party provides its written consent to such disclosure, such consent not to be unreasonably withheld.

Section 7.5Notwithstanding the foregoing, the receiving Party may disclose Confidential Information pursuant to the lawful requirement or request of a governmental agency or otherwise required to be disclosed by law, rule, regulation, or rules of a securities exchange, provided that where available, reasonable measures are taken to obtain confidential treatment thereof and to guard against further disclosure, and further provided that where practicable, reasonable written notice is provided to the disclosing Party to enable the disclosing Party to seek protection of the confidentiality of such Confidential Information, with which the receiving Party shall assist in any reasonable way. The Parties agree that Confidential Information (including, without limitation, the terms of this Agreement) that is publicly disclosed in accordance with a Party’s obligations under applicable securities laws and regulations, the rules and regulations of the U.S. Securities and Exchange Commission or any national securities exchange will no longer be deemed Confidential Information under this Agreement.

Section 7.6Upon termination or expiration of this Agreement, the receiving Party shall cease all use of the Confidential Information of the disclosing Party (except as otherwise provided in this Agreement) and, upon request, shall either (a) promptly return within thirty (30) days all such Confidential Information, including any copies thereof, or (b) promptly destroy all such Confidential Information and certify such destruction to the disclosing Party; provided, however, that the receiving Party may retain a single copy thereof for the sole purpose of determining the scope of the obligations incurred under this Agreement.

Article VIII
MISCELLANEOUS

Section 8.1Assignment or Transfer. Neither Party may assign this Agreement or any of its rights and obligations thereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign its rights and obligations under the Agreement to an Affiliate or subsidiary of such Party, and further provided that either Party may assign this Agreement to any party that acquires either all or substantially all of the stock of such Party or such Party’s assets and operations related to the purpose of this Agreement. Any assignments or transfers in violation of this Section 8.1 shall be void. This Agreement shall be binding on any successors or assignees authorized by this Section 8.1.

10

 

 

 

Section 8.2Indemnification; Limitations of Liability. Each Party shall indemnify, defend, and hold harmless the other party from and against any loss, liability, claim, or action (whether or not meritorious), to persons, property, or third parties (“Loss”), to the extent that such Loss (a) arises out of the breach of any of the warranties or covenants set forth in this Agreement; or (b) was caused by the negligence or intentional wrongdoing of the indemnifying party or its agents, subcontractors, or Affiliates. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY UNDER THIS AGREEMENT FOR ANY INDIRECT, CONSEQUENTIAL, PUNITIVE, SPECIAL, OR INCIDENTAL DAMAGES.

Section 8.3Insurance. During the Agreement Term, each Party shall maintain workers’ compensation insurance with limits of not less than two million ($2,000,000) dollars per occurrence and two million ($2,000,000) dollars in the aggregate, and commercial general liability insurance with limits of not less than one million ($1,000,000) dollars per occurrence and two million ($2,000,000) dollars in the aggregate.

Section 8.4Expenses. Each Party shall be responsible for any costs and expenses, including professional fees, that such Party incurs in connection with performing its obligations under this Agreement.

Section 8.5Force Majeure. If a Party is delayed in fulfilling any of the terms and conditions hereunder due to acts of God, war, prohibitions on exports or imports, fires, floods, strikes, sabotage, civil commotion or riots, earthquakes, or any other cause beyond such Party’s reasonable control (each a “Force Majeure Event”), time for such performance by such Party shall be extended by the period of time equal to that caused by such delay in performance. Once the Force Majeure Event ceases to exist, all terms and conditions of this Agreement will again prevail. The foregoing is subject to the right of termination set forth in Section 5.4(b) herein.

Section 8.6Nature of Relationship. Nothing in this Agreement shall be deemed or construed to constitute or create between the Parties hereto a partnership, joint venture or agency. Neither Aimmune nor Supplier shall engage in any conduct that might create the impression or inference that Aimmune or Supplier, as applicable, is a partner, joint venturer, or officer of the other. Supplier hereby certifies that it is engaged in an independent business and will perform its obligations under this Agreement as an independent contractor and not as the agent or employee of Aimmune.

Section 8.7Separability of Clauses. Any provision or provisions of this Agreement that in any way contravene the law of any state or country in which this Agreement is effective shall, in such state or country, to the extent of such contravention of law, be deemed separable and shall not affect any other provisions hereof or the validity hereof.

Section 8.8Notices. All notices and other communications hereunder shall be in writing and sent to the applicable address set forth below, or to another address if specified by like notice, and shall be deemed given when, as applicable: (a) delivered personally; or (b) received or refused, if mailed by registered or certified mail (return receipt requested), postage prepaid, or reliable overnight courier service; provided, however, that notices of a change of address shall be effective only upon receipt thereof:

11

 

 

 

If to Aimmune: Aimmune Therapeutics, Inc.
8000 Marina Boulevard, Suite 300 Brisbane, CA 94005
Attn: Chief Operating Officer

With a copy to:

Aimmune Therapeutics, Inc.
8000 Marina Boulevard, Suite 300 
Brisbane, CA 94005
Attn: General Counsel

If to Supplier:Golden Peanut Company, LLC,
100 North Point Center East, Suite 400 
Alpharetta, GA 30022
Attn: President 

With a copy to:

Archer Daniels Midland Company 
77 W. Wacker Drive, Suite 4600 
Chicago, IL 60601
Attn: Chief Counsel – Oilseeds

Section 8.9Entire Agreement. This Agreement, together with all attachments hereto, and the Securities Agreement set forth the entire agreement and understanding between the Parties on the subject matter thereof, and merges all prior discussions and negotiations between them. Any other written or oral agreement relating to the subject matter hereof existing between the Parties, including without limitation the Prior Agreement, is expressly canceled as of the Effective Date. Neither of the Parties shall be bound by any conditions, definitions, representations, or warranties with respect to the subject matter of this Agreement other than as expressly provided herein or as duly set forth on or subsequent to the date hereof in a writing signed by duly authorized representatives of both Parties. This Agreement cannot be modified or amended through statements appearing on any Purchase Order or invoice.

Section 8.10Governing Law. This Agreement and its formation, operation, and performance shall be governed, construed, performed, and enforced in accordance with the substantive laws of the State of Illinois, without regard to its conflict of laws principles. Exclusive jurisdiction for litigation of any dispute, controversy, or claim arising out of or in connection with this Agreement, or breach thereof, shall be only in the Federal or State court with competent jurisdiction located in Cook County, Chicago, Illinois.

Section 8.11Paragraph Headings. Paragraph headings have been inserted solely for the convenience of the Parties and shall not be considered a part of this Agreement for interpretation or construction.

Section 8.12Publicity. Neither Party shall use the other Party’s name or trademarks in any advertising or promotional efforts of any kind without the prior written permission of such Party. For clarity, this Section 8.12 will not apply to any legally required disclosures.

12

 

 

 

Section 8.13Access. Supplier acknowledges that Aimmune is subject to extensive federal and state laws and regulations that provide, among other things, that vendors that provide Aimmune with products, supplies, equipment or services that may be used in the production or testing of medicines or pharmaceuticals or that may affect medical or pharmaceutical data must meet certain regulatory minimum validation requirements, and that Aimmune must perform quality assurance audits on any such vendors and must allow health authority access as requested. Supplier agrees to cooperate with Aimmune in satisfying these requirements, as applicable, including by allowing Aimmune (or its designated representatives) and health authorities to perform any necessary audits of Supplier’s records and/or facilities and by providing Aimmune and health authorities with any necessary information and materials. Supplier will provide Aimmune with notice as soon as practicable but not more than three business days from the time Supplier learns of any inspection or audit conducted or proposed to be conducted by the FDA, the EMA or other regulatory agency of any Supplier facility used to produce Product if such inspection or audit is with respect to an Aimmune regulatory filing or otherwise could negatively affect Supplier’s ability to provide Aimmune with Product in accordance with this Agreement or Aimmune’s ability to develop, manufacture or commercialize the Treatment.

Section 8.14Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original.

Section 8.15Waiver. No waiver of any provision of this Agreement or any right or obligation of a Party shall be effective unless in writing and signed by the Parties. The failure of either Party to enforce a right shall not constitute a waiver.

 

13

 

 

 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date.

		
	
SUPPLIER:
	
AIMMUNE THERAPEUTICS, INC.:

	
 

By: /s/ Greg Mills
	
 

By: /s/ Stephen G. Dilly

	
Name: Greg Mills
	
Name: Stephen G. Dilly

	
Title: President
	
Title: President and Chief Executive Officer

 

 

 

 

 

Exhibit A

Pricing

 

 

 

 

 

SPECIALTY PRODUCTS

PRICE LIST

 

[***]

Product Codes:[***]

VOLUME: PER POUND

[***]$[***]
[***]$[***]
[***]$[***]
[***]$[***]

 

PACKAGING:50 lb. (22.68 kilo) multiwall paper bags – 40 bags (2,000 lbs.) / pallet

 

FREIGHT CONDITIONS:Freight collect. F.O.B. [***]

 

TERMS:Net 30 days with approved credit

 

SAMPLE SIZE: 1 lb. (0.45 kg)

 

 

 

 

All pricing is subject to change without notice. Final price is that recorded in the written confirmation.01/18

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

 

SPECIALTY PRODUCTS

PRICE LIST

 

[***]

Product Codes:[***]

VOLUME: PER POUND

[***]$[***]
[***]$[***]
[***]$[***]
[***]$[***]

 

PACKAGING:50 lb. (22.68 kilo) multiwall paper bags – 40 bags (2,000 lbs.) / pallet

 

FREIGHT CONDITIONS: Freight collect. F.O.B. [***]

 

TERMS:Net 30 days with approved credit

 

SAMPLE SIZE:1 lb. (0.45 kg)

 

 

 

All pricing is subject to change without notice. Final price is that recorded in the written confirmation.01/18

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

 

Exhibit B

Product Specifications

 

 

 

 

 

 

SPECIALTY PRODUCTS

[***]
Product Code [***]

DESCRIPTION:
[***]

FLAVOR:[***]

SUGGESTED APPLICATIONS:

ConfectionsSeasoning BlendsSauces
Baked GoodsNutritional BarsDry Flavors

INGREDIENT DECLARATION:[***]

LABEL DECLARATION:[***]

				
	
TYPICAL ANALYSIS:
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

 

PACKAGING:50 lb. (22.7 kg.) multi-wall paper – poly lined bags – 40 bags/pallet

SAMPLE SIZE:1 lb.KOSHER: OU HALAL: I.S.A.

STORAGE CONDITIONS:Cool / Dry

SHELF LIFE:12 months when stored in original packaging.

COUNTRY OF ORIGIN: Product of U S A.

This information contained herein is correct to the best of our knowledge. The recommendations or suggestions contained in this bulletin arc made without guarantee or representation as to results. We suggest that you evaluate these recommendations and suggestions in your own laboratory prior to use. Our responsibility for claims arising from breach of warranty, negligence, or otherwise is limited to the purchase price of the material. Freedom to use any patent owned by Golden Peanut Company, LLC or others is not be inferred from any statement contained herein.

[***]Oct-17

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

SPECIALTY PRODUCTS

[***]
Product Code [***]

DESCRIPTION:
[***]

FLAVOR:[***]

SUGGESTED APPLICATIONS:
ConfectionsReduced Fat Peanut ButtersSauces
Baked GoodsNutritional BarsFillings

INGREDIENT DECLARATION:[***]

LABEL DECLARATION:[***]

				
	
TYPICAL ANALYSIS:
	
 
	
 
	
 

	
[***]

 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

PACKAGING:50 lb. (22.7 kg.) multi-wall paper – poly lined bags – 40 bags/pallet

SAMPLE SIZE:1 lb. KOSHER:OUHALAL:I.S.A.

STORAGE CONDITIONS: Cool / Dry

SHELF LIFE:12 months when stored in original packaging.

Country of Origin: Product of USA

This information contained herein is correct to the best of our knowledge. The recommendations or suggestions contained in this bulletin are made without guarantee or representation as to results. We suggest that you evaluate these recommendations and suggestions in your own laboratory prior to use. Our responsibility for claims arising from breach of warranty, negligence, or otherwise is limited to the purchase price of the material. Freedom to use any patent owned by Golden Peanut Company, LLC or others is not be inferred from any statement contained herein.

[***]Oct-16

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

SPECIALTY PRODUCTS

[***]
Product Code [***]

DESCRIPTION:
[***]

FLAVOR:[***]

SUGGESTED APPLICATIONS:
ConfectionsSeasoning BlendsPet TreatsDry Peanut Butter
Baked GoodsNutritional BarsDry FlavorsSmoothies

INGREDIENT DECLARATION: [***]

LABEL DECLARATION:[***]

				
	
TYPICAL ANALYSIS:
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

PACKAGING:50 lb. (22.7 kg.) multi-wall paper – poly lined bags – 40 bags/pallet

SAMPLE SIZE:1 lb.KOSHER:OUHALAL:I.S.A.

STORAGE CONDITIONS: Cool / Dry

SHELF LIFE:12 months when stored in original packaging.

COUNTRY OF ORIGIN: Product of USA

This information contained herein is correct to the best of our knowledge. The recommendations or suggestions contained in this bulletin are made without guarantee or representation as to results. We suggest that you evaluate these recommendations and suggestions in your own laboratory prior to use. Our responsibility for claims arising from breach of warranty, negligence, or otherwise is limited to the purchase price of the material. Freedom to use any patent owned by Golden Peanut Company, LLC or others is not be inferred from any statement contained herein.

[***]Oct-16

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

SPECIALTY PRODUCTS

[***]
Product Code [***]

DESCRIPTION:
[***]

FLAVOR:[***]

SUGGESTED APPLICATIONS:
ConfectionsSeasoning BlendsPet TreatsFillings
Baked GoodsNutritional BarsDry FlavorsSmoothies

INGREDIENT DECLARATION: [***]

LABEL DECLARATION:[***]

				
	
TYPICAL ANALYSIS:
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 

PACKAGING:50 lb. (22.7 kg.) multi-wall paper – poly lined bags – 40 bags/pallet

SAMPLE SIZE: 1 lb.KOSHER: OU HALAL: I.S.A.

STORAGE CONDITIONS: Cool / Dry

SHELF LIFE:12 months when stored in original packaging.

COUNTRY OF ORIGIN: Product of USA

This information contained herein is correct to the best of our knowledge. The recommendations or suggestions contained in this bulletin are made without guarantee or representation as to results. We suggest that you evaluate these recommendations and suggestions in your own laboratory prior to use. Our responsibility for claims arising from breach of warranty, negligence, or otherwise is limited to the purchase price of the material. Freedom to use any patent owned by Golden Peanut Company, LLC or others is not be inferred from any statement contained herein.

[***]Oct-16

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

EXHIBIT C-l

Product

(product code [***]
(product code [***]
(product code [***]
(product code [***] 

 

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

EXHIBIT C-2

Product

(product code [***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]